How do I buy Adaptive Biotech (ADPT) stock?

Buying Adaptive Biotech (ADPT) stock is now easy and instant through the Gotrade app. Download the Gotrade app from the App Store or Google Play. Create an account and complete KYC. Make a deposit. Search for the code "ADPT", then tap "Trade". Tap the "Buy" button. Enter the amount you want to buy. You have two options: Buy ADPT by number of shares. Buy fractional shares in dollars, starting from $1. Swipe up to confirm your order, and you're done!

How do I tell if ADPT is expensive or cheap?

There's no single perfect answer, but common approaches include: Compare valuation (e.g., P/E, P/S) against historical averages or competitors. Review revenue and earnings growth. Check margins and cash flow. Evaluate business outlook and the company's position within its industry. You can combine fundamental analysis with an investing strategy that matches your risk profile. All of the information above can be viewed directly in the Gotrade app.

Adaptive Biotech (ADPT) Stock

Q: What is the minimum investment for ADPT on Gotrade?

On Gotrade , you don't have to buy a full lot. With fractional shares, you can start investing in Adaptive Biotech from just $1. A small budget shouldn't stop you from building a US stock portfolio.

NSQ · ADPT

Trade ADPT

Key stats

Market cap: $4.12B
Price / Earnings ratio: -64.5x
EPS (TTM): -$0.41
Volume: Loading
52-week high: $30.74
52-week low: $12.00
EPS vs analyst estimate: 0.0%Q3 FY25 · -$0.15 vs -$0.15

Source: third-party data provider, as of November 5, 2026

EPS estimate: analyst consensus

Compare with ADPT

Technical indicators

RSI 14: 51.93
MACD 12/26/9: 0.02
EMA 9 of MACD: -0.05
MACD histogram: 0.07
SMA 50: $26.37; Price above SMA 50
EMA 50: $25.86; Price above EMA 50
SMA 200: $19.73; Price above SMA 200
EMA 200: $20.88; Price above EMA 200

Calculated by Gotrade from daily closing prices, as of November 4, 2026. Technical data, not a recommendation.

Analyst ratings

Analyst consensus: Buy

Based on 5 analyst ratings

Strong Sell0

Sell0

Hold1

Buy4

Strong Buy0

Third-party analyst opinion, not a recommendation from Gotrade.

Financials

Performance

Revenue

Net income

Net margin %

2022

2023

2025

332M219M110M0

Debt & Balance Sheet

Total assets

Total liabilities

2022

2023

2025

1B678M339M0

Revenue to Profit

2025

$277.0M

Revenue

$0.0

Cost of revenue

$205.6M

Gross profit

$0.0

Operating expenses

$-59.5M

Net income

Earnings

EPS forecast

Actual EPS

$-0.15

Q3FY25

$-0.18

Q4FY25

$-0.17

Q1FY26

$-0.15

Q2FY26

$-0.15

Q3FY26

The market is expecting earnings per share of -$0.15 for this quarter. The company has not yet shared when it is announcing earnings.

Source: third-party data provider

About Adaptive Biotech

Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed to develop products in life sciences research, clinical diagnostics, and drug discovery. We have three commercial products, and a robust clinical pipeline to diagnose, monitor and enable the treatment of diseases such as cancer, autoimmune conditions and infectious diseases.

SectorHealthcare

IndustryBiotechnology

Employees624

CEOMr. Chad M. Robins M.B.A.

IPO DateJun 25, 2014

HeadquartersSeattle, WA

Key Executives

Name	Title	Year Born
Mr. Chad M. Robins M.B.A.	Co-Founder, CEO & Chairman	1975
Ms. Julie Rubinstein	President & COO	1972
Mr. Kyle Piskel	VP, CFO & Principal Accounting Officer	1984
Ms. Susan Bobulsky	Chief Commercial Officer of MRD	1981
Mr. Christopher Carlson Ph.D.	Founder	—
Ms. Karina Calzadilla	VP of Investor Relations and FP&A	—
Ms. Clarice McCauley	Head of Legal, Corporate Secretary, VP & Chief Compliance Officer	—
Mr. Francis T. Lo	Chief People Officer	1981
Dr. Sharon Benzeno Ph.D.	Chief Commercial Officer of Immune Medicine	1974
Ms. Mary Pat Lancelotta	Senior Vice President of MRD BioPharma	—

Seasonality

Monthly price change (%)

	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
2021											-28.5	+11.4
2022	-39.7	-18.9	-2.6	-44.0	-9.7	+10.8	+8.8	-2.6	-20.3	+7.3	+4.4	-11.7
2023	+18.8	-8.8	+8.6	-18.0	-5.3	-4.8	+26.3	-17.9	-20.0	-14.5	-1.4	+4.3
2024	-23.1	+9.9	-20.3	-15.8	+23.7	+9.4	+26.4	+5.6	+14.0	-3.6	+11.9	-8.1
2025	+25.2	+7.3	-8.3	-2.1	+29.3	+22.0	-8.5	+27.6	+16.5	+19.2	+13.4	-13.8
2026	+16.3	-12.9	-13.9	-2.3	+6.2	+40.8	+0.9	+7.8	+18.7	-2.7	+6.6

Stocks in the same sector

Vertex Pharmaceuticals

ABEO

Abeona Therapeutics Inc.

Agios Pharmaceuticals, Inc.

FAQ

Buying Adaptive Biotech (ADPT) stock is now easy and instant through the Gotrade app.

Download the Gotrade app from the App Store or Google Play.
Create an account and complete KYC.
Make a deposit.
Search for the code "ADPT", then tap "Trade".
Tap the "Buy" button.
Enter the amount you want to buy. You have two options:
1. Buy ADPT by number of shares.
2. Buy fractional shares in dollars, starting from $1.
Swipe up to confirm your order, and you're done!

On Gotrade, you don't have to buy a full lot. With fractional shares, you can start investing in Adaptive Biotech from just $1. A small budget shouldn't stop you from building a US stock portfolio.

At the moment, Adaptive Biotech (ADPT) does not pay dividends because it focuses on reinvesting profits for company growth (a growth stock). However, you can still potentially earn profit from share price increases (capital gains). Track ADPT's performance via the price chart in the Gotrade app.

Gotrade is the trading name of Gotrade Securities Inc., which is registered with and supervised by the Labuan Financial Services Authority (LFSA).

You can place orders 24/7. Transactions will be executed when the US market (NYSE/NASDAQ) is open, from 9:30 PM to 4:00 AM WIB, or 8:30 PM to 3:00 AM WIB during Daylight Saving Time. Gotrade also provides access to pre-market and after-hours trading, so you have more flexibility and aren't limited to regular working hours.

Market hours may change due to daylight saving time and holidays. In Gotrade, you can see the market status (open/closed) directly in the app.

There's no single perfect answer, but common approaches include:

Compare valuation (e.g., P/E, P/S) against historical averages or competitors.
Review revenue and earnings growth.
Check margins and cash flow.
Evaluate business outlook and the company's position within its industry.

You can combine fundamental analysis with an investing strategy that matches your risk profile. All of the information above can be viewed directly in the Gotrade app.

Trade Faster. Easier. Smarter.

#ReadyGoTrade

Welcome Reward up to $1,888

Create an account and trade US stocks on Gotrade

Download app

*Terms & conditions apply

Adaptive Biotech (ADPT) Stock

Key stats

Compare with ADPT

Recent news

Adaptive Biotechnologies Corporation (ADPT) Hit a 52 Week High, Can the Run Continue?

Adaptive Biotechnologies Corporation (ADPT) Hit a 52 Week High, Can the Run Continue?

Adaptive Biotechnologies (ADPT) Reports Q2 Earnings: What Key Metrics Have to Say

Adaptive Biotechnologies (ADPT) Reports Q2 Earnings: What Key Metrics Have to Say

Adaptive Biotechnologies (ADPT) Reports Q2 Loss, Beats Revenue Estimates

Adaptive Biotechnologies (ADPT) Reports Q2 Loss, Beats Revenue Estimates

Adaptive Biotechnologies Q2 Earnings Call Highlights

Adaptive Biotechnologies Q2 Earnings Call Highlights

Technical indicators

Analyst ratings

Financials

Performance

Debt & Balance Sheet

Revenue to Profit

Earnings

Latest news

Adaptive Biotechnologies Corporation (ADPT) Hit a 52 Week High, Can the Run Continue?

Adaptive Biotechnologies Corporation (ADPT) Hit a 52 Week High, Can the Run Continue?

Adaptive Biotechnologies (ADPT) Reports Q2 Earnings: What Key Metrics Have to Say

Adaptive Biotechnologies (ADPT) Reports Q2 Earnings: What Key Metrics Have to Say

Adaptive Biotechnologies (ADPT) Reports Q2 Loss, Beats Revenue Estimates

Adaptive Biotechnologies (ADPT) Reports Q2 Loss, Beats Revenue Estimates

Adaptive Biotechnologies Q2 Earnings Call Highlights

Adaptive Biotechnologies Q2 Earnings Call Highlights

Adaptive Biotechnologies (ADPT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Adaptive Biotechnologies (ADPT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Adaptive Biotechnologies (ADPT) Upgraded to Buy: What Does It Mean for the Stock?

Adaptive Biotechnologies (ADPT) Upgraded to Buy: What Does It Mean for the Stock?

An Adaptive Biotechnologies Insider Sold $8.5 Million in Stock After an 85% Run

An Adaptive Biotechnologies Insider Sold $8.5 Million in Stock After an 85% Run

Adaptive Biotechnologies plans separation of immune medicine platform

Adaptive Biotechnologies plans separation of immune medicine platform

What Does an Adaptive Biotech Insider's Sale of Nearly 40,000 Shares Mean for Investors?

What Does an Adaptive Biotech Insider's Sale of Nearly 40,000 Shares Mean for Investors?

Adaptive Biotechnologies (ADPT) Moves 9.7% Higher: Will This Strength Last?

Adaptive Biotechnologies (ADPT) Moves 9.7% Higher: Will This Strength Last?

About Adaptive Biotech

Key Executives

Fundamentals

Valuation

Profitability

Trading

Technical indicators

Analyst views

Seasonality

Compare stocks

Market cap

Price / Earnings ratio

Price / Sales ratio

Dividend yield

Average volume

Earnings per share

Stocks in the same sector

FAQ

Trade Faster. Easier. Smarter.

#ReadyGoTrade